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ABSTRACT: The folate antagonist methotrexate is a cyto-
toxic drug used in the treatment of several cancer types. The
entry of methotrexate into the cell is mediated by two main
transport systems: the reduced folate carrier and membrane-
associated folate receptors. These transporters diﬀer consid-
erably in their mechanism of (anti)folate uptake, substrate
speciﬁcity, and tissue speciﬁcity. Although the mechanism of
action of the reduced folate carrier is fairly well-established,
that of the folate receptor has remained unknown. The devel-
opment of speciﬁc folate receptor-targeted antifolates would
be accelerated if additional mechanistic data were to become available. In this work, we used two ﬂuorescently labeled
conjugates of methotrexate, diﬀerently linked at the terminal groups, to clarify the uptake mechanism by folate receptor-α. The
results demonstrate the importance of methotrexate amino groups in the interaction with folate receptor-α.
The folate antagonist methotrexate (MTX) was introducedinto oncology as a cytotoxic antiproliferative agent that
has been used in the treatment of various cancer types for
decades.1 It is an antimetabolite that inhibits dihydrofolate
reductase (DHFR), which is an enzyme involved in the biosyn-
thetic pathway of nucleotides, and MTX is therefore highly
toxic to rapidly dividing cancer cells.2
The ﬁrst pivotal step in the cellular pharmacology of MTX is
its entry into the cell, which can be mediated by two general
transport systems: the reduced folate carrier (RFC) and
membrane-associated folate receptors (FRs). These transport
routes are physiologically and pharmacologically relevant for
immunocompetent cells because they facilitate the uptake of
natural reduced folate cofactors and folate antagonists, such as
MTX.3 The RFC and FRs diﬀer considerably in their mech-
anism of (anti)folate uptake (transmembrane carrier vs endo-
cytosis), substrate speciﬁcity (low-aﬃnity folic acid/high-
aﬃnity MTX vs high-aﬃnity folic acid/low-aﬃnity MTX),
and tissue speciﬁcity (constitutive vs restricted expression)
(Figure 1).
The membrane-spanning anion transporter RFC has a con-
stitutive expression in essentially all human tissues, providing a
high-aﬃnity bidirectional exchange mechanism for reduced
folate cofactors and MTX (Km = 1−10 μM). Inversely, the RFC
binding aﬃnity for folic acid is low (Ki = 200−400 μM).4,5
A second folate transport mechanism is mediated by FR, a
particulate form of folate binding proteins, which are anchored
to the cell membrane by glycosylphosphatidylinositol (GPI)
residues. FRs have a mass of 38−40 kDa and are encoded by
two genes (FR α and β) with diﬀerential tissue expression. The
α-isoform of FR is overexpressed in speciﬁc types of cancer
(e.g., ovarian cancer),6 while the β isoform on activated
macrophages.7 The third member of this gene family, γ-type, is
a secretory protein, from hematopoietic cells, because of the
lack of a signal for GPI attachment.8 Unlike RFC, FR exhibits a
much greater aﬃnity for folic acid and 5-methyltetrahydrofo-
late (Kd = 1−10 nM) but lower for other reduced folates and
MTX (Kd = 10−300 nM). FRs also have diﬀerent properties in
terms of energy, ion, and pH dependence.4 The level of
binding of folate to FR is decreased after energy depletion and
in the absence of chloride anion but does not decrease until the
pH falls below 5.0.9
The functional activity of the RFC-mediated cellular traﬃc
of antifolates with antitumor activity in vivo is fairly well-
established.5 On the contrary, the exact role and mechanism of
action of the FRα have remained unclear.10 In 2013, the
structure−activity relationship for molecular (high-aﬃnity) recog-
nition of folate and folate conjugates by FRα was disclosed.11
It was demonstrated that FRα has a globular structure stabilized by
eight disulﬁde bonds and contains a folate binding pocket formed
of conserved residues (across all receptor subtypes).11 The
molecular model reveals that the glutamate moiety is solvent-
exposed and projects from the receptor’s pocket entrance, enabling
cargo attachment without obstructing FRα binding.11 This struc-
ture helps explain the low binding aﬃnity of MTX for FRα,
because it shows that there is a steric impediment of a speciﬁc
amino group that interferes with the binding to the receptor.
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Knowing the molecular recognition details and considering
that MTX is transported into cells via the FR rather than
through facilitative transporters (expressed in normal tissues),
one could not expect damage to normal cells.12 Therefore,
FRα-targeted therapy should focus on overcoming the aﬃnity
and speciﬁcity for MTX, over RFC. This could be achieved
through engineering of molecules that take advantage of the
many solvent-ﬁlled cavities that surround ligands in the folate
receptor binding cleft.12
In the study presented here, we elucidate the mechanism of
uptake of MTX by FRα. Two ﬂuorescently labeled conjugates
of MTX, diﬀerently linked at the terminal groups, were used
for cellular uptake, and molecular docking and molecular
dynamics simulations were performed to validate their ﬁndings.
■ METHODS
Fluorescent Labeling of MTX.MTX was labeled with the
amino-reactive ﬂuorescent dye Red Mega 520 NHS-ester
(ﬂuorescent red), as previously described for folic acid.13
Brieﬂy, 140 μL of an MTX solution [3.7 mg/mL in a 3:1 mix-
ture of 50 mM bicarbonate buﬀer (pH 9) and dimethylforma-
mide (DMF)] was mixed with 28 μL of a ﬂuorescent red solu-
tion (20 mg/mL in DMF), and 200 μL of DMF was added.
The mixture was shaken for 4 h at 25 °C under light protec-
tion. The product was puriﬁed by size exclusion chromatog-
raphy using a HiTrap Desalting column (GE Healthcare
Europe GmbH, Vienna, Austria) installed on an Äkta Puriﬁer
system (Amersham Pharmacia Biotech, Uppsala, Sweden) with
50 mM potassium phosphate and 100 mM NaCl (pH 7) as the
eluent, at the ﬂow rate of 1 mL/min, to remove excess ﬂuo-
rescent red. Fractions, which showed absorbance at 520 nm for
ﬂuorescent red and 368 nm for MTX, were collected. Elec-
trospray ionization (ESI) was performed in a Thermo Finnigan
LxQ mass detector (Linear Ion Trap). The mass detector was
susceptible of analysis in full scan mode, SIM and MS/MS with
negative ionization. The mass spectral range was from 50 to
2000. The capillary voltage was 29 V. MTX concentrations
were determined photometrically by comparison with a calibration
curve. According to the manufacturer’s instructions (Sigma-Aldrich
Co., St. Louis, MO), ﬂuorescent Mega dyes have a large Stokes
shift among excitation and emission maxima, compatible with
the same excitation conditions (light source or ﬁlter arrange-
ment) as the ﬂuorescent green ﬂuorescein isothiocyanate
(FITC). As such, the commercial ﬂuorescent green conjugate
of MTX (Molecular Probes|Life Technologies), linked through
the carboxyl groups, was further considered for the cellular
uptake experiments.
Cell Culture Conditions. The epithelial cancer cell line
KB (ATCCCCL-17) and the MDA-MB-435S human
melanoma cells (ATCCHTB-129) were obtained from the
American Type Culture Collection. The KB cell line was
maintained in Roswell Park Memorial Institute (RPMI)-1640
Medium (without folic acid) containing 2 mM L-glutamine and
2 mg/mL sodium bicarbonate supplemented with 10% (v/v)
fetal bovine serum (FBS) and a 1% (v/v) penicillin/
streptomycin solution. The MDA-MB-435S cell line was main-
tained in Dulbecco’s modiﬁed Eagle’s medium (DMEM)
containing 4 mM L-glutamine, 4.5 g/L glucose, and 1.5 g/L
sodium bicarbonate supplemented with 10% (v/v) FBS and a
1% (v/v) penicillin/streptomycin solution. Cells were main-
tained at 37 °C in a humidiﬁed atmosphere of 5% CO2. Cells
were routinely subcultured over 2 to 3 days.
FR Conﬁrmation by Real-Time Quantitative Polymer-
ase Chain Reaction (qPCR). Cell lysates of diﬀerent-origin
cancer lines were collected, and total RNA was extracted using
the “SV Total RNA Isolation System”, according to the manu-
facturer’s protocol (Promega Corp.). Following column elution
with 30 μL of RNase-free water, the RNA concentration was
determined by measuring the absorbance at 260 nm in a
NanoDrop ND-1000 spectrophotometer (A260 = 1−40 μg/mL)
(Nanodrop Technologies). The A260/A280 ratio was calculated to
estimate RNA purity. Reverse transcription was performed using
the “iScriptTM cDNA synthesis kit” (Bio-Rad Laboratories).
Unique blended oligo(dT) and random hexamer primers were
incubated according to the manufacturer’s protocol as follows:
5 min at 25 °C, 60 min at 42 °C, 5 min at 85 °C, and hold
Figure 1. Schematic representation of folate receptor-mediated endocytosis and methotrexate inﬂux. The folic acid has a 100−200-fold greater
aﬃnity for the folate receptor than for the reduced folate carrier. Inversely, the reduced folate carrier binding aﬃnity for methotrexate is higher.
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at 4 °C. For conﬁrmation of FRα and RFC expression levels,
TaqMan probe-based gene expression assays (Applied
Biosystems, Spain) were considered: Hs01124177_m1 and
Hs00953345_m1, respectively. Real-time qPCRs were per-
formed in a CFX96 Real-Time PCR Detection System, with a
C1000TM thermal cycler (Bio-Rad Laboratories). The ampli-
ﬁcation process used the following conditions: UNG incubation
at 50 °C for 2 min, polymerase activation at 95 °C for 10 min,
denaturation at 95 °C for 15 s, and annealing/extension at 60 °C
for 60 s, for 50 cycles (data collection). A stable endogenous
control gene, cyclin-dependent kinase inhibitor 1A, CDKN1A
(TaqMan assay Hs00355782_m1; Applied Biosystems, Spain),
was used for normalization of the expression values.
Uptake Experiments. The FRα-positive cells (KB cancer
cell line) and MDA-MB-435S cells (negative control) were
harvested from the culture vessel during their S-phase (i.e.,
until a monolayer, with a conﬂuence of >60%, was obtained)
and seeded at a density of 100000 cells/mL (24-well micro-
plates) for the uptake experiments. After an overnight period
to ensure optimal adhesion, the culture medium was removed,
and adherent cells were washed twice with acidic phosphate-
buﬀered saline (pH 3.5) to remove bound folic acid. The MTX
conjugates were diluted in Hanks’ balanced salt solution
(folate-free) at a nontoxic (data not shown) concentration of
6 μM (adjusted for antifolate concentration) and incubated in
cancer cells for 4 h. The same experiment was repeated using
medium containing 113 μM free folic acid (Sigma) and
calcium folinate (TCI) to determine the eﬀect of FR and RFC
blockade, respectively. The cultures were maintained under
a humidiﬁed atmosphere containing 5% CO2 in a 37 °C
incubator. The internalized concentration of MTX conjugates
was determined, considering the ﬂuorescence intensity mea-
sured (PerkinElmer LS-50B luminescence spectrometer) upon
lysis of the exposed cells. All values were corrected by the
intensity/molarity ratio, according to calibration curves of
ﬂuorescently labeled conjugates.
Molecular Docking Simulations. The computational
models of FRα, RFC, and MTX have diﬀerent origins. The
FRα model corresponds to entry 4KM6 of the RCSB Protein
Data Bank (PDB),14 that is an X-ray diﬀraction of human FRα
(FOLR1) at acidic pH. The software Modeler (https://salilab.
org/modeller)15 was used to obtain a three-dimensional model
of RFC protein, through homology with a structure of a trans-
membrane glucose transporter obtained by X-ray diﬀraction
(PDB entry 4ZW9),16 due to the lack of a full crystallographic
model of RFC. Finally, the MTX structure was obtained using
the “Automated Topology Builder (ATB) and Repository”
online server (https://atb.uq.edu.au/)17 using AM1-optimized
geometry and MOPAC charges.
The models of FRα, RFC, and MTX were preprocessed with
Autodock tools18 to correct the charges, the hydrogens, and
the bond ﬂexibility when needed. Later, Autodock Vina19 was
used to perform the docking simulations between FRα and
MTX and between RFC and MTX to evaluate the binding
aﬃnity between them. All docking calculations were performed
with one 5 nm × 5 nm × 5 nm box centered on the FR active
site, and the exhaustiveness was varied between 80 and 800.
Molecular Dynamics Simulations. The simulations were
performed with the GROMACS 4.6.520 package using the
GROMOS 54A7 force ﬁeld.21,22 The initial conﬁgurations of
the protein−MTX conjugates were the result of docking
simulations with higher binding energies. These structures
were solvated and simulated for a few nanoseconds (∼10 ns).
The bond lengths of the proteins were constrained with
LINCS,23 and those for water with SETTLE.24 Nonbonded
interactions were calculated using a twin-range method, with
short- and long-range cutoﬀs of 0.8 and 1.4 nm, respectively.
Neighbor searching was performed up to 1.4 nm and updated
every two steps. A time step of integration of 2 fs was used.
A reaction ﬁeld correction for the electrostatic interactions was
applied using a dielectric constant of 54.25 The single-point
charge model26 was used for water molecules. The initial systems
were energy minimized for 2000 steps using the steepest descent
method, with all heavy atoms harmonically restrained using a
force constant of 103 kJ mol−1 nm−2.
The systems were initialized in the canonical ensemble
(NVT) for 50 ps, with all heavy atoms harmonically restrained
using a force constant of 103 kJ mol−1 nm−2. The simulation
was then continued for picoseconds in the isothermal−isobaric
ensemble (NPT), with the heavy atoms harmonically
restrained with the same force constant. Finally, to allow the
equilibration of the system properties, the simulations were
further extended in the NPT ensemble with position restraints
applied to only the α-carbons. Pressure control was implemented
using the Berendsen barostat,27 with a reference pressure of 1 bar,
a relaxation time of 0.5 ps, and an isothermal compressibility
of 4.5 × 10−5 bar−1. Temperature control was set using the
V-rescale27,28 thermostat at 300 K with coupling constants of
0.025 ps in the ﬁrst two initialization steps and 0.1 ps for the
rest of the simulations. At least three replica systems were
simulated for each condition, from 50 ns using diﬀerent initial
velocities taken from a Maxwell−Boltzman distribution at 300 K.
GROMACS tools were used to evaluate several properties of the
systems, such as the pressure, temperature, and surface accessible
solvent area, providing insights into the correct modeling of
the protein−MTX interaction.
Figure 2. Molecular structures (most probable) of the tested
conjugates. (A) Red Mega-HN-MTX-COOH and (B) H2N-MTX-
CO-FITC. Fluorescent red dye can also be linked to the amino group
marked with a circle, but because the conjugate was puriﬁed by size
exclusion chromatography, the occurrence of a 2/1 (Mega dye/MTX)
conjugate is excluded, as it would have a larger size and therefore a
shorter retention time. The MTX−Red Mega 520 conjugate was
analyzed by ESI, and the observed mass peak (m/z 951.02)
corresponds to the theoretical molecular weight (data not shown).
The ﬂuorescent green dye is linked to the carboxyl groups of MTX as
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In addition, pulling simulations were performed with
FR−MTX and RFC−MTX conjugates, with a constant force
of 1000 kJ mol−1 nm−2 and a rate of 0.1 nm/ns applied to the
MTX molecule. The force applied in the MTX molecule
obliges the molecule to exit from the active sites of the tested
proteins. The MTX had its carboxyl group termination facing
the solvent in both cases. Later an umbrella sampling method-
ology29 was applied to calculate the potential of mean force for
the process of MTX molecules exiting the FRα and RFC
proteins.
■ RESULTS AND DISCUSSION
In this work, two ﬂuorescently labeled conjugates of MTX,
diﬀerently linked at the terminal groups (Figure 2), were
considered for cellular uptake. Because high levels of FRα were
Figure 3. (A) Analysis of FRα and RFC expression levels in human cancer cell lines. (B) Uptake concentrations of the ﬂuorescently labeled MTX
conjugates by cancer cell lines: FRα-positive KB and FRα-negative MDA-MB-435S. RFC expression levels and uptake of the H2N-MTX-CO-FITC
conjugate were also analyzed after incubation of cells with folic acid and calcium folinate. Values are presented as means ± the standard error of two
independent experiments. Diﬀerences were tested for statistical signiﬁcance by a one-way analysis of variance (*P < 0.005; ***P < 0.001).
Figure 4. Molecular docking and molecular dynamics simulations. (A) Docking result showing MTX at the active site of FRα with the amino
groups facing the protein. The docking result was the starting point of the molecular dynamics. (B) Docking result showing MTX at the active site
of FRα with the carbonyl groups facing the protein. The docking result was the starting point of the molecular dynamics. (C) System A after a
simulation run of 1 ns to ensure stabilization. This was the starting point of the umbrella pulling procedure. (D) System B after a simulation run of
1 ns to ensure stabilization. The conﬁguration derived from the docking was not stable, and after a short simulation, MTX is no longer at the active
site of the receptor.
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reported in a wider spectrum of epithelial-origin tissues,30
human epithelial adenocarcinoma cells of the mammary gland
were selected for exposure to the antifolate conjugates, in
comparison to a negative control. The FRα expression levels of
the diﬀerent-origin cancer cells were quantiﬁed using a stan-
dardized real-time qPCR detection system. The concentration
of the conjugates internalized (adjusted for MTX concen-
tration) was determined, considering the ﬂuorescence measured
in the lysates of the exposed cells. To ascertain the “targetability”
of FRα, molecular docking simulations of the FRα−MTX
complex were performed.
This study adds information to the current understanding of
the structural underpinnings of the transport of antifolate-
based derivatives. Moreover, the interference of the chemical
nature of their free terminal groups on the aﬃnity and/or
speciﬁcity of the molecular interactions involved in their
cellular uptake was evaluated. The functional chemical groups
of the MTX conjugates implicated in the binding to the
surface-associated receptor, and their potential as a “tool” to
surmount the membrane-spanning anion transporter, avoiding
signiﬁcant side eﬀects and dose-limiting toxicities, are discussed.
Prior to cellular uptake experiments, FRα expression levels
of the diﬀerent-origin human cancer cells were conﬁrmed.
Real-time qPCR data analysis revealed higher expression levels
of FRα in the KB cancer cell line and negligible levels in the
MDA-MB-435S cell line (Figure 3A).11 Although posttran-
scriptional regulation can occur, previous studies showed that
the level of protein expression of FR31,32 and RFC33,34 in
several cancer cell lines is directly proportional to mRNA levels.
The uptake concentration of the MTX conjugates, diﬀer-
ently linked at the terminal functional groups, showed signif-
icant interaction among the selected factors. For FRα-positive
cells, KB, signiﬁcant statistical diﬀerences were observed among
the internalized concentrations of the two MTX conjugates,
whereas for the FRα-negative cells, MDA-MB-435S, negligible
diﬀerences were observed (Figure 3B). Comparable amounts
of both MTX conjugates, with either terminus blocked, were
taken up similarly by FRα-negative cells. It is noteworthy that,
although H2N-MTX-CO-FITC internalization remains unal-
tered after incubation with a high-aﬃnity FR substrate (folic
acid),35 as expected, it is possible to observe an increase in the
level of internalization after incubation with the high-aﬃnity
RFC substrate (calcium folinate).36 Once RFC expression
remains similar after incubation with the high-aﬃnity RFC
substrate (Figure 3A), one can speculate that another uptake
mechanism is present or is activated in the presence of a huge
quantity of the calcium folinate.
Higher concentrations of the H2N-MTX-CO-FITC con-
jugate were taken up by FRα-positive cells compared to that of
the Red Mega-HN-MTX-COOH conjugate (Figure 3B). This
result provides a proof of concept of higher passage of MTX
via FRα when the amino groups are free. Furthermore, as
expected, the level of internalization of the H2N-MTX-CO-FITC
conjugate decreases after incubation with the high-aﬃnity FR
substrate, folic acid, remaining unaltered after incubation with
the high-aﬃnity RFC substrate, calcium folinate.
The receptors FRα and FRβ have high degrees of sequence
identity (82%) and similarity (92%), with their binding sites
being highly conserved, with only two divergent residues
(V129α/F123β and K158α/R152β).12 Although we did not
perform studies with cell lines expressing FRβ, a behavior similar
to that of FRα would be expected.
The ability of the conjugate with free amino groups to bind
to FRα was further conﬁrmed by molecular docking and molec-
ular dynamics simulations, as shown in Figure 4. Molecular
docking experiments initially suggested that MTX is capable of
binding to FRα using either the terminal amino group (Figure 4A)
or the terminal carboxylic group (Figure 4B). However, stabi-
lization of these docking structures in water, using molecular
dynamics simulation tools, showed that the complex is stable
only if the amino groups are facing the FRα pocket and not the
opposite.
Taking into account the molecular dynamics simulations, we
calculated the binding energy between the two transport
systems and MTX, using an umbrella sampling technique to
calculate the potential of mean force. The ﬁnal result demo-
nstrates that the complex of MTX and RFC is stronger, with a
binding energy of approximately 65 kcal mol−1, comparatively
Figure 5. Potentials of mean force of MTX with RFC and FRα.
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with FRα, with a binding energy of approximately 15 kcal mol−1
(Figure 5).
In summary, the obtained outcomes provide a rationale
for designing more speciﬁc drugs for selective approaches.
Modulation of the MTX terminal groups might be a potentially
useful strategy for improved mediated transport targeting
through the FRα system on cancer cells (Figure 6). A major
outcome anticipated from this study is the development of the
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